Liping Wang

TL;DR: The current knowledge concerning the roles of IFN-γ in the TME as a part of the complex immune response to cancer is discussed and the importance of identifying IFn-γ responsive patients to improve their sensitivity to immuno-therapies is highlighted.

TL;DR: A fraction of CD11b+CD33+ myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues from non-small cell lung cancer (NSCLC) patients expressed surface ectonucleotidases CD39 and CD73, providing novel targets for chemo-immunotherapeutic intervention.

TL;DR: It is shown that metformin treatment blocks the suppressive function of myeloid-derived suppressor cells (MDSC) in patients with ovarian cancer by downregulating the expression and ectoenzymatic activity of CD39 and CD73 on monocytic and polymononuclear MDSC subsets.

TL;DR: Under the pressure applied by anti-PD1/PDL1 therapy, tumors experience immunoediting and preserve beneficial mutations, upregulate the compensatory inhibitory signaling and induce re-ex exhaustion of T cells, all of which may attenuate the durability of the therapy.

TL;DR: Results suggest that the IL6–CXCR7 axis may provide a promising target for the treatment of ESCC, with significantly worse overall survival and progression-free survival upon receiving cisplatin after operation.